Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.
Prior guidance: "Looking forward, for the full year, the Company expects the trajectory of full year revenue growth to cont...
ChromaDex (NASDAQ:CDXC) reported quarterly sales of $22.739 million which missed the analyst consensus estimate of $23.437 mill...
Results from the at-home test kit are available to HCPs and their patients through 1healthChromaDex Corp. (NASDAQ:CDXC), the gl...
-SEC Filing
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide ribos...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:CDXC) with a Buy and maintains $6 price target.
